Tim Lugo
Stock Analyst at William Blair
(0.15)
# 4,383
Out of 5,178 analysts
22
Total ratings
20%
Success rate
-37.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tim Lugo
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VTGN Vistagen Therapeutics | Downgrades: Market Perform | n/a | $0.61 | - | 4 | Dec 17, 2025 | |
| BMRN BioMarin Pharmaceutical | Downgrades: Market Perform | n/a | $55.59 | - | 3 | Oct 30, 2024 | |
| LENZ LENZ Therapeutics | Initiates: Outperform | n/a | $9.07 | - | 1 | Apr 15, 2024 | |
| SLDB Solid Biosciences | Initiates: Outperform | $40 | $7.23 | +453.25% | 1 | Mar 28, 2024 | |
| ZVRA Zevra Therapeutics | Initiates: Outperform | n/a | $9.13 | - | 1 | Mar 12, 2024 | |
| ABBV AbbVie | Upgrades: Outperform | n/a | $207.18 | - | 2 | Jan 29, 2024 | |
| ACRS Aclaris Therapeutics | Downgrades: Market Perform | n/a | $3.59 | - | 1 | Nov 13, 2023 | |
| TVTX Travere Therapeutics | Downgrades: Market Perform | n/a | $27.56 | - | 1 | Sep 21, 2023 | |
| SPRY ARS Pharmaceuticals | Downgrades: Market Perform | n/a | $7.90 | - | 2 | Sep 20, 2023 | |
| AVIR Atea Pharmaceuticals | Initiates: Outperform | n/a | $5.43 | - | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $55.57 | - | 1 | Jan 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $0.14 | - | 2 | Sep 22, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.40 | - | 1 | May 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $46 | $8.61 | +434.26% | 1 | May 30, 2017 |
Vistagen Therapeutics
Dec 17, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $0.61
Upside: -
BioMarin Pharmaceutical
Oct 30, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $55.59
Upside: -
LENZ Therapeutics
Apr 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $9.07
Upside: -
Solid Biosciences
Mar 28, 2024
Initiates: Outperform
Price Target: $40
Current: $7.23
Upside: +453.25%
Zevra Therapeutics
Mar 12, 2024
Initiates: Outperform
Price Target: n/a
Current: $9.13
Upside: -
AbbVie
Jan 29, 2024
Upgrades: Outperform
Price Target: n/a
Current: $207.18
Upside: -
Aclaris Therapeutics
Nov 13, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $3.59
Upside: -
Travere Therapeutics
Sep 21, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $27.56
Upside: -
ARS Pharmaceuticals
Sep 20, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $7.90
Upside: -
Atea Pharmaceuticals
Nov 24, 2020
Initiates: Outperform
Price Target: n/a
Current: $5.43
Upside: -
Jan 8, 2020
Initiates: Outperform
Price Target: n/a
Current: $55.57
Upside: -
Sep 22, 2017
Upgrades: Outperform
Price Target: n/a
Current: $0.14
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $2.40
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: $46
Current: $8.61
Upside: +434.26%